Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALUE-CHECK: Reduced Frequency ICI Dosing in Advanced Cancers
NCT06422403Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, atezolizumab and pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 2 more (6 cohorts), sponsored by National University Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06422403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422403.